Market research
MRIC ClearPoint Neuro, Inc
NYSE USD Other
Latest close
As of 29 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 80M
- P/E ratio
- Not available
- Analyst target
- 20
- Dividend yield
- 0.0%
- Beta
- Not available
Profile
Instrument facts
- Exchange
- NYSE
- Currency
- USD
- Sector
- Other
- Industry
- Other
- ISIN
- Not available
- Market cap
- 80M
- P/E ratio
- Not available
- Analyst target
- 20
- Dividend yield
- 0.0%
- Beta
- Not available
About
About ClearPoint Neuro, Inc
MRI Interventions, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for placing catheters, electrodes, and laser fibers to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, a product candidate designed to allow catheter-based minimally invasive procedures in the heart to be performed using continuous, intra-procedural MRI guidance. The company has a development agreement with Mayo Clinic to design and develop MRI-guided therapies for stroke; and a collaborative license and co-development agreement with Clinical Laserthermia Systems AB to provide navigation and laser ablation platforms for use in spine and neurosurgery. MRI Interventions, Inc. was founded in 1998 and is headquartered in Irvine, California.
Research context
ClearPoint Neuro, Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Other
- Industry
- Other
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the MRIC discussion.
5 years, 7 months ago
From a valuation standpoint, the stock is 342.5% more expensive than other stocks from the Other sector with a price to sales ratio of 4.1.
Based on the above factors, ClearPoint Neuro, Inc gets an overall score of 0/5.